- Home
- TYGO vs IMMX Comparison
TYGO vs IMMX Comparison
Compare TYGO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- IMMX
- Stock Information
- Founded
- TYGO 2007
- IMMX 2014
- Country
- TYGO United States
- IMMX United States
- Employees
- TYGO N/A
- IMMX 21
- Industry
- TYGO Semiconductors
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- TYGO Technology
- IMMX Health Care
- Exchange
- TYGO Nasdaq
- IMMX Nasdaq
- Market Cap
- TYGO 60.2M
- IMMX 54.9M
- IPO Year
- TYGO N/A
- IMMX 2021
- Fundamental
- Price
- TYGO $1.01
- IMMX $2.47
- Analyst Decision
- TYGO Strong Buy
- IMMX Strong Buy
- Analyst Count
- TYGO 2
- IMMX 1
- Target Price
- TYGO $3.75
- IMMX $7.00
- AVG Volume (30 Days)
- TYGO 21.1K
- IMMX 360.1K
- Earning Date
- TYGO 05-06-2025
- IMMX 06-10-2025
- Dividend Yield
- TYGO N/A
- IMMX N/A
- EPS Growth
- TYGO N/A
- IMMX N/A
- EPS
- TYGO N/A
- IMMX N/A
- Revenue
- TYGO $63,051,000.00
- IMMX N/A
- Revenue This Year
- TYGO $69.44
- IMMX N/A
- Revenue Next Year
- TYGO $21.75
- IMMX N/A
- P/E Ratio
- TYGO N/A
- IMMX N/A
- Revenue Growth
- TYGO N/A
- IMMX N/A
- 52 Week Low
- TYGO $0.58
- IMMX $1.26
- 52 Week High
- TYGO $1.85
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- TYGO 60.26
- IMMX 62.87
- Support Level
- TYGO $0.92
- IMMX $1.89
- Resistance Level
- TYGO $1.04
- IMMX $2.47
- Average True Range (ATR)
- TYGO 0.06
- IMMX 0.17
- MACD
- TYGO 0.00
- IMMX 0.01
- Stochastic Oscillator
- TYGO 75.00
- IMMX 81.97
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.